2020 / 04

Next Paper
DOI: 10.24075/brsmu.2020.050

METHOD

New in vitro model to evaluate kinetics of antimycobacterial drug release from bioresorbable polymeric carriers

Andreevskaya SN1, Smirnova TG1, Antonov EN2, Chernousova LN1, Bogorodsky SE2, Larionova EE1, Popov VK2, Ergeshov A1
About authors

1 Laboratory of Biotechnology, Central Tuberculosis Research Institute, Moscow, Russia

2 Institute of Photon Technologies FSRC ‘Crystallography and Photonics’ RAS, Moscow, Russia

Correspondence should be addressed: Sofia N. Andreevskaya
Yauzskaya alleya, d. 2, str. 1A., Moscow, 107564; ur.liam@aifosdna

About paper

Funding: the study was supported by the Russian Ministry of Science and Higher Education and carried out as part of the State Assignment for FSRC “Crystallography and Photonics” RAS (developing an SCF-based method for creating bioactive matrices), as part of the State Assignment № 0515-2019-0015 (Formation of resistance to antimycobacterial drugs in mycobacteria and somatic cells) for the Central Tuberculosis Research Institute (evaluation of the bacteriostatic activity of different levofloxacin concentrations). The study was also supported by the Russian Foundation for Basic Research (Project № 18-29-06062 mk: development of sustained-release therapeutic formulations and an in vitro model for the evaluation of their efficacy).

Compliance with ethical standards: manipulations with virulent strains of M. tuberculosis were conducted in compliance with the safety guidelines for the experiments involving Risk Group III–IV pathogens, infectious agents and utilization of medical waste specified in sanitary regulations 1.3.2322-08, 1.3.2518-09, 1.3.2885-11, and 2.1.7.2790-10.

Author contribution: Andreevskaya SN — interpretation of study results, manuscript preparation; Smirnova TG — modeling of conditions for levofloxacin release from its carriers; discussion of study results; Antonov EN — preparation of matrices; discussion of study results; Chernousova LN, Ergeshov AE — study design; discussion of study results; Bogorodsky SE — preparation of microparticles; discussion of study results; Larionova EE — literature analysis; discussion of study results; Popov VK — method for antibiotic encapsulation into polymeric carriers; discussion of study results.

Received: 2020-08-06 Accepted: 2020-08-20 Published online: 2020-08-30
|
  1. World Health Organization. Global tuberculosis report 2019. Geneva: World Health Organization, 2019.
  2. Bogorodskii SE, Krotova LI, Mironov AV, Popov VK. Fabrication of highly porous bioresorbable polymer matrices Using Supercritical Carbon Dioxide. Russian Journal of Physical Chemistry B. 2013; 7 (8): 916–23.
  3. Alsenz J, Kansy M. High troughput solubility measurement in drug discovery and development Adv Drug Del Rev. 2007; 59: 546.
  4. Antonov EN, Bogorodskiy SE, Dunayev AG, Krotova LI, Mariyanats AO, Syachina MA, i dr. Razrabotka komponentov antibakterial'nykh lekarstvennykh form prolongirovannogo deystviya s ispol'zovaniyem SKF-tekhnologiy. Sverkhkriticheskiye flyuidy: teoriya i praktika. 2020; 15 (1): 124–35. Russian.
  5. Yehia SA, Elshafeey AH, Elsayed I. A novel injectable in situ forming poly-DL-lactide and DL-lactide/glycolide implant containing lipospheres for controlled drug delivery. J Liposome Res. 2012; 22 (2): 128–38.
  6. Ahmed T. Review: approaches to develop PLGA based in situ gelling system with low initial burst. Pak J Pharm Sci. 2015; 28 (2): 657–65.
  7. Ergeshov AE, editor. Tuberkulez organov dykhaniya. Rukovodstvo dlya vrachey. M.: Galleya-Print, 2017; 524 s. Russian.
  8. Chernousova LN, Sevastyanova EV, Larionova EE, Smirnova TG, Andreyevskaya SN, i dr. Federal'nyye klinicheskiye rekomendatsii po organizatsii i provedeniyu mikrobiologicheskoy i molekulyarno-geneticheskoy diagnostiki tuberkuleza. Tver': Triada, 2014; 29 s.
  9. Matyugina E, Khandazhinskaya A, Chernousova L, Andreevskaya S, Smirnova T, Chizhov A, et al. The synthesis and antituberculosis activity of 50-nor carbocyclic uracil derivatives. Bioorganic and Medicinal Chemistry. 2012; 20: 6680–86.
  10. Bhardwaj A, Kumar L, Narang RK, Murthy RS. Development and characterization of ligand-appended liposomes for multiple drug therapy for pulmonary tuberculosis. Artif Cells Nanomed Biotechnol. 2013; 41 (1): 52–9.
  11. Sorokoumova GM, Yasin YaOH, Mikulovich YuL, Smirnova TG, Andreyevskaya SN, Selishcheva AA, i dr. Sozdaniye i izucheniye svoystv liposomal'noy formy levofloksatsina. Tonkiye khimicheskiye tekhnologii. 2013; 8 (5): 72–6. Russian.
  12. Andreevskaya SN, Smirnova TG, Zhogina YA, Smirnova DI, Mikulovich YL, Sorokoumova GM, et al. Effect of exogenous cardiolipin on the growth and viability of Mycobacterium tuberculosis H37Rv in vitro. Dokl Biol Sci. 2010; 434: 371–4.
  13. Qiao Z, Yuan Z, Zhang W, Wei D, Hu N. Preparation, in vitro release and antibacterial activity evaluation of rifampicin and moxifloxacin-loaded poly(D,L-lactide-co-glycolide) microspheres. Artif Cells Nanomed Biotechnol. 2019; 47 (1): 790–8.
  14. Quenelle DC, Staas JK, Winchester GA, Barrow EL, Barrow WW. Efficacy of microencapsulated rifampin in Mycobacterium tuberculosis-infected mice. Antimicrob Agents Chemother. 1999; 43 (5): 1144–51.
  15. Kailasam S, Daneluzzi D, Gangadharam PR. Maintenance of therapeutically active levels of isoniazid for prolonged periods in rabbits after a single implant of biodegradable polymer. Tuber Lung Dis. 1994; 75 (5): 361–5.
  16. Gangadharam PR, Kailasam S, Srinivasan S, Wise DL. Experimental chemotherapy of tuberculosis using single dose treatment with isoniazid in biodegradable polymers. J Antimicrob Chemother. 1994; 33 (2): 265–71.
  17. Kumar G, Malhotra S, Shafiq N, Pandhi P, Khuller GK, Sharma S. In vitro physicochemical characterization and short term in vivo tolerability study of ethionamide loaded PLGA nanoparticles: potentially effective agent for multidrug resistant tuberculosis. J Microencapsul. 2011; 28 (8): 717–28.
  18. Dutt M, Khuller GK. Therapeutic efficacy of Poly(DL-lactide- Co-Glycolide)-encapsulated antitubercular drugs against Mycobacterium tuberculosis infection induced in mice. Antimicrob Agents Chemother. 2001; 45 (1): 363–6.
  19. Naydenova AA, Sukoyan GV, Vorontsov EA, Kuznetsov SL, Gukasova NV, Ryabtseva MS, i dr. Razrabotka nanosomal'nykh kompozitsiy rifampitsina i D-tsikloserina na osnove polilaktidglikolidov i issledovaniye ikh protivotuberkuleznoy aktivnosti. Nanotekhnologii i okhrana zdorov'ya. 2012; 3 (12): 23–30. Russian.